GFAP-Cre–Mediated Activation of Oncogenic K-ras Results in Expansion of the Subventricular Zone and Infiltrating Glioma

Ty W. Abel,1 Cara Clark,1 Brian Bierie,2 Anna Chytil,2 Mary Aakre,2 Agnieszka Gorska,2 and Harold L. Moses2

Abstract

A subset of neoplastic cells within human high-grade gliomas has features associated with stem cells. These cells may sustain glioma growth, and their stem-like properties may confer resistance to standard glioma treatments. Whether glioma stem cells derive from indigenous neural stem cells (NSC), or from tumor cells that have reacquired stem cell-like properties, is unknown. However, signaling pathways that are tightly regulated and central to NSC biology, including the Ras/Raf/Erk pathway, are hyperactive and pathogenic in gliomagenesis. Furthermore, data in animal models suggests that, in some cases, tumors are initiated in the subventricular zone (SVZ), a stem/progenitor cell niche in the mature brain. We activated oncogenic K-ras in mouse glioneuronal precursor cells and adult SVZ cells using GFAP-Cre. GFAP-Cre+/K-ras<sup>G12D</sup> mice showed a marked expansion of glial fibrillary acidic protein (GFAP)- and TUJ1–expressing cell populations in the SVZ. In addition, mice developed intermediate grade, infiltrating glioma with 100% penetrance. Tumors were consistently located in the amygdalohippocampal region and nearby cortex, often in association with the lateral ventricle and expanded SVZ. Tumor cells expressed markers associated with neural progenitor cells, including Olig2, Bmi-1, and PDGFR-α. These data suggest that infiltrating tumor cells may arise from NSC transformed by activation of oncogenic K-ras<sup>in vivo</sup>. (Mol Cancer Res 2009;7(5):645–53)

Introduction

High-grade gliomas are aggressive cancers that are generally refractory to standard treatment modalities. As such, they are among the most deadly of human neoplasms. Recent studies indicate that some neoplastic cells within human high-grade glioma have the capacity for self-renewal and multilineage differentiation, properties associated with normal neural stem cells (NSC; refs. 1-4). It is hypothesized that these stem-like tumor cells are responsible for tumor growth and recurrence after therapy, making them attractive targets for novel glioma therapies (5-7). Furthermore, the ability of glioma stem cells (GSC) to differentiate along multiple lineages may underlie the histopathologic and clinical heterogeneity of glial neoplasms (2, 5). The mechanisms by which a fraction of glioma cells acquires stem-like properties are currently unknown. One hypothesis is that GSC arise from neoplastic transformation of endogenous NSC (5, 8-11). Another possibility is that transformed, lineage-committed precursor or fully differentiated cells reacquire stem-like properties (11, 12).

The best characterized stem cell population in the mature mammalian brain resides in the subventricular zone (SVZ)/rostral migratory stream (RMS; refs. 13-16). Evidence suggests that this area is composed of both stem cells and early lineage-restricted precursor cells (14, 15). Glial fibrillary acidic protein (GFAP)-expressing, type B cells may represent the true stem cell in this population (14, 17). These cells give rise to GFAP-negative, type C, or transit-amplifying cells (14, 15). In turn, type A cells arise from transit-amplifying cells and express markers of early neuronal differentiation (14, 15). In a similar fashion, the GSC hypothesis suggests that glioma cells are arranged hierarchically (5). GSC may divide symmetrically or asymmetrically, giving rise to two daughter GSC, to one GSC and one lineage-restricted tumor cell, or to two lineage-restricted precursor cells. NSC and GSC may be studied in vitro, where they grow suspended in the culture medium in clusters known as “neurospheres” or “gliomaspheres,” respectively. The addition of serum and withdrawal of growth factors results in differentiation of neurosphere and gliomasphere cells into those that express neural, astrocytic, and oligodendroglial phenotypes (2, 18).

Parallels between NSC and GSC extend beyond the capacities for self-renewal and multilineage differentiation. Many of the signaling pathways that regulate NSC proliferation, differentiation, and migration are aberrantly regulated in glioma via mutation and/or overexpression of genes that encode for key effector or regulatory molecules (19). Evidence suggests that Ras/Raf/Erk signaling is one such pathway.

Through receptor tyrosine kinases, Ras signaling regulates important aspects of NSC biology. Type B cells have been shown to express platelet-derived growth factor (PDGF) receptor (PDGFR), whereas type C cells express epidermal...
growth factor (EGF) receptor (EGFR; refs. 20, 21). Furthermore, intraventricular infusion of EGF or PDGF results in expansion of the SVZ and “glioma-like growths” (20, 21). Type C cells become highly invasive of surrounding brain and adopt a more glial phenotype in response to long-term, intraventricular infusion of EGF (20). These studies suggest the possibility that hyperactive Ras signaling in NSC could initiate gliomagenesis.

To test this hypothesis, we used the Cre-lox system to target a mutant and constitutively active form of K-ras to NSC in vivo. The GFAP-Cre mouse line, originally developed and characterized by Albee Messing’s group, was used (22). Our data (data not shown), using Rosa26 reporter (Rosa26r) mice and immunohistochemistry for Cre, are in accord with the findings of other groups, showing widespread recombinase activity and/or Cre expression in neurons, glia, and a subset of GFAP-expressing SVZ precursors in the mature GFAP-Cre mouse brain (9, 22, 23). Activation of oncogenic K-ras with GFAP-Cre results in both expansion of the SVZ and development of multifocal, infiltrating, intermediate-grade glioma by age 2 months. Proximity of the neoplasm to the expanded stem cell compartment and the expression by tumor cells of markers associated with NSC and GSC suggest that transformed stem/progenitor cells may give rise to the infiltrating tumor cells in vivo.

Results

Oncogenic K-ras Activation Results in Marked Expansion of the SVZ/RMS

GFAP-Cre transgenic mice were crossed with mice in which expression of oncogenic K-ras (K-ras<sup>G12D</sup>) is silenced by a stop signal flanked by loxP sequences. GFAP-Cre<sup>+/K-rasG12D</sup> progeny seem normal at birth. However, at age ~4 weeks the mice develop largely benign, squamous papillary lesions. This is likely due to endogenous expression of GFAP in normal mouse skin, as shown by Western blot analysis (data not shown). These lesions are slowly growing but attain sufficient size such that mice must be sacrificed by age ~2.5 months (mean, 77.9 days; range, 44–127 days; n = 7).

Examination of the brain at the time of euthanasia revealed no macroscopic abnormalities. Histologic examination, however, showed a marked expansion of the SVZ/RMS compared with age-matched controls (Figs. 1 and 2). In GFAP-Cre<sup>+/K-rasG12D</sup> mice, the mean width of the SVZ was increased >4-fold compared with controls (n = 7 experimental and 6 control animals per group; P = 0.0005; Fig. 1). The expanded cell layer was composed of at least two cell types based on morphology and immunohistochemistry. The predominant cell type was located closest to the ependymal layer and had oval to angular, hyperchromatic nuclei and scant cytoplasm (Fig. 2A and C, bar). Apoptotic bodies and mitotic figures were abundant. These cells did not express GFAP (Fig. 2B and D). The second cell type formed a distinct layer in many cases and had round nuclei with open chromatin (Fig. 2A and C, bracket). These cells were strongly immunoreactive with antibody for GFAP (Fig. 2B and D). On the other hand, the GFAP-negative cells were immunoreactive for TUJ1, a marker of early neuronal differentiation (Fig. 2E). These data suggest that expression of oncogenic K-ras in the SVZ/RMS results in expansion of both GFAP-expressing type B cells as well as lineage-restricted cells with neuronal differentiation. Ki67 immunohistochemistry showed a high proliferation index in the expanded cell layer, particularly in the GFAP-/TUJ1<sup>+</sup> compartment (Fig. 2F). Cre expression was present largely in the GFAP-expressing compartment (Fig. 2G), and both cell types showed high levels of phosphorylated mitogen-activated protein kinase (p-MAPK; Fig. 2H); these data confirm expression of the GFAP-Cre transgene and are consistent with activation of the Ras pathway in these cells. p-MAPK levels were low to undetectable in neurons and glia outside the SVZ/RMS (Fig. 2H and I).

Activation of Oncogenic K-ras Results in Multifocal, Intermediate-Grade Glioma

In addition to expansion of the stem/progenitor cell compartment, GFAP-Cre<sup>+/K-rasG12D</sup> mice developed bilateral, multifocal, infiltrating glioma with 100% penetrance. In many cases, the tumors involved the amygdalohippocampal region or nearby cortex. The neoplasms were characterized at low magnification by foci of hypercellularity on H&E stain (Figs. 3A-C and 4A). The infiltrating tumor cells had hyperchromatic, oval to angular nuclei and scant cytoplasm (Fig. 3A-C). The tumor

**FIGURE 1.** The adult stem/progenitor cell compartment was markedly expanded in GFAP-Cre<sup>+/K-rasG12D</sup> compared with littermate control mice. The SVZ/RMS stream is a stem/progenitor cell compartment in the mature brain and on parasagittal section consists of a thin layer of cells adjacent to the lateral ventricle and corpus callosum (A, Arrows; right, original magnification, ×40; v, ventricle; cc, corpus callosum; ST, striatum). In GFAP-Cre<sup>+/K-rasG12D</sup> mice, both the vertical and horizontal limbs of the SVZ/RMS are increased in size (A, Left; original magnification, ×40). Compared with control mice, the thickness of the vertical limb of the SVZ, measured at the single widest point, was increased >4-fold in GFAP-Cre<sup>+/K-rasG12D</sup> mice (B, n = 7 mutant and 6 control mice per group; P = 0.0005).
cells formed rings around overrun neurons (“satellitosis”; Fig. 3A and C) and accumulated beneath the pia mater (Fig. 3B), a histoarchitecture that is common in human glioma. Scattered mitotic figures were identified on H&E stain (Fig. 3C, arrow), and many more were highlighted with immunohistochemistry for phospho-histone3, a marker for cells in mitosis (Fig. 3D, arrows). The neoplastic cells showed strong immunoreactivity for TUJ1, a marker of immature neurons (E), and they did not express GFAP (B and D). Conversely, the smaller cells were immunoreactive for GFAP (B and D) and did not express TUJ1 (E). Both cell types were highly proliferative, as indicated by Ki67 immunohistochemistry (F, Original magnification, x200). The cells expressed Cre protein (G, Original magnification, x200) and high levels of p-MAPK (H, Original magnification, x200; v, ventricle), consistent, respectively, with expression of the GFAP-Cre transgene and activation of the Ras pathway in these cells. Note the absence of significant p-MAPK labeling outside the expanded SVZ/RMS (I and H). p-MAPK signal is low to undetectable in cortex from the same animal shown in H (I, Original magnification, x200). Arrow, the ependymal layer in all panels.

Infiltrating Glioma Cells in GFAP-Cre+/K-ras<sup>G12D</sup> Mice Express Markers Associated with “Stemness”

In human glioma specimens, a subset of neoplastic cells expresses markers that have been associated with stem cell biology. Olig2 is a bHLH transcription factor that has been linked to proliferation and lineage specification in NSC as well as the stem-like population of tumor cells in human high-grade gliomas (25). Immunohistochemical staining of tumor sections in GFAP-Cre+/K-ras<sup>G12D</sup> mice showed strong staining of tumor cell nuclei (Fig. 5A and B). Tumor cells were also immunoreactive for PDGFR-α, which is expressed by both normal NSCs and human glioma cells (Fig. 5C; refs. 21, 26). Bmi-1 has been implicated in the self-renewal properties of both NSC and stem cells associated with brain tumors (27, 28). The majority of tumor cells in GFAP-Cre+/K-ras<sup>G12D</sup> mice showed strong nuclear expression of Bmi-1 (Fig. 5D). Examination in adjacent sections of tumor cells in areas of subpial accumulation, a normally paucicellular region now composed almost exclusively of foci of tumor, the glomeruloid microvascular proliferation and necrosis characteristic of human grade IV tumors was not present. Therefore, the gliomas in GFAP-Cre+/K-ras<sup>G12D</sup> mice most closely resemble intermediate grade (grade 2-3) human glioma.
tumor cells, confirmed the coexpression of these stemness markers.

Tumor Foci Are Present in Continuity with the Ventricles and Expanded SVZ

The amygdalohippocampal area and nearby structures were infiltrated by atypical, proliferating cells in nearly all (6 of 7) cases, and involvement of this region was bilateral in most. This suggests a common origin for the tumor cells. Indeed, portions of the amygdalohippocampal area and related structures are in direct contact with the SVZ of the lateral ventricle. Examination of other regions near the ventricles revealed small foci of atypical, infiltrating cells resembling those found in larger foci of tumor (Fig. 6A and B). Furthermore, in regions of frank SVZ expansion, cells labeling with Olig2 and Ki67 were observed in surrounding brain parenchyma, including the striatum and cortex (Fig. 6C and D). These observations indicate that the tumors in GFAP-Cre+/K-ras\(^{G12D}\) mice have a predilection for regions near the ventricles and that expression of oncogenic K-ras alters the migratory behavior of SVZ stem/progenitor cells.

Discussion

Unlike many human tumors, Ras mutation is not common in human glioma. However, increased Ras activity has been shown in these tumors, and at least three likely mechanisms for this have been identified. First, the receptor tyrosine kinases EGFR and PDGFR reside upstream of Ras and are often overexpressed in glioma (29). Furthermore, a constitutively active, mutant form of EGFR (EGFRvIII) is commonly expressed in human glioma (29). Neurofibromatosis type I is a neurocutaneous syndrome in which afflicted individuals are predisposed to glioma, often of the low-grade variety. This disorder is caused by mutations in the gene that encodes neurofibromin, a negative regulator of Ras activity (30). Finally, a recent report showed increased copies of Ras genes in over 40% of human glioma specimens (31). Thus, the Ras pathway is central to human gliomagenesis. Emerging evidence suggests that the Ras signaling cascade also regulates NSC biology, including proliferation, differentiation, and migration (20, 21). We simulated hyperactivity in the Ras pathway by activating oncogenic K-ras in the brain using a GFAP-Cre transgene. This results in marked expansion of the SVZ/RMS and multifocal, intermediate grade glioma.

Our data (data not shown) regarding the expression pattern of the GFAP-Cre transgene, in this particular strain of GFAP-Cre mice, are consistent with previous reports (9, 22, 23). In the adult brain, Cre protein was expressed by mature astrocytes and a subset of SVZ cells (data not shown). Although mature neurons did not express Cre, crosses with Rosa26r mice showed β-galactosidase activity, and thus recombination, in these cells as well. Two mechanisms could account for the expression of Cre
in SVZ cells. First, a subset of these cells (type B cells) expresses GFAP in the mature mouse brain (14, 15, 17). Second, the transgene is expressed in radial glia during embryogenesis, as early as embryonic day 12.5 (9, 22). Fate-mapping studies indicate that these cells ultimately give rise to adult neurons, astrocytes, and SVZ progenitor cells (23, 32-34). Because Cre-mediated recombination is irreversible, all of the progeny of radial glia would be expected to express oncogenic K-ras. Thus, although expression is not limited to the SVZ in adult mice, GFAP-Cre mice may be used to target expression of oncogenes to adult stem cells in vivo.

β-Galactosidase staining and Cre immunohistochemistry show the cellular compartments in which expression of oncogenic K-ras is possible, i.e., those cells in which Cre has removed the stop signal that silences expression of K-rasG12D. However, because the oncogene is targeted to the endogenous K-ras promoter, cell-specific mechanisms likely regulate the degree of expression in a given cell type. We used p-MAPK immunohistochemistry as a readout for activation of the Ras pathway in GFAP-Cre+/K-rasG12D mice. The results clearly showed that the highest levels of p-MAPK are found in the SVZ/RMS and in the infiltrating tumor cells, with relatively little or no staining in neurons and mature astrocytes. Thus, despite the presence of recombination throughout the brain in multiple cell types, the greatest degree of Ras pathway activation was in the SVZ/RMS and the infiltrating tumor cells.

The gliomas that arise in GFAP-Cre+K-rasG12D mice were diffusely infiltrating and highly reminiscent of intermediate grade, human glioma. Satelliteitis and subpial accumulation are patterns associated with, but not specific for, oligodendroglioma. However, the expression of GFAP and the cytologic features of the tumor cells on H&E more closely resembled human astrocytoma. The mice were not obviously symptomatic from these lesions and were sacrificed due to skin tumors at a mean age of 77.9 days. Therefore, it is unknown whether the gliomas would have progressed to a higher grade over time. The phenotype is highly penetrant, however, with 100% of mice developing lesions at a relatively young age.

Other mouse glioma models have been reported in which Ras signaling has been manipulated in the brain. Our results are consistent with Ding et al. (35), who described low- and high-grade gliomas in mice using another Ras isoform (v12-H-ras) under direct control of the human GFAP promoter. Tumor development is associated with spontaneous acquisition of p53 mutations in astrocytes overexpressing this Ras isoform (36). Another study, in which GFAP-Cre mice were crossed with the K-rasG12D strain, failed to detect brain tumors in the bigenic, GFAP-Cre+/K-rasG12D progeny (37). Similarly, targeting K-rasG12D to either nestin-expressing neural progenitor cells

FIGURE 4. Compared with sections from the same anatomic brain region in a littermate control mouse (B, D, and F) tumor foci in mutant mice (A, C, and E) showed an approximate 3-fold increase in cellularity (A versus B. Original magnification, ×200). Ki67 immunohistochemistry labeled many of the neoplastic cells but was largely negative in control brains (C versus D. Original magnification, ×200). Many of the tumor cells were immunoreactive for GFAP (E. Original magnification, ×200), which labels normal astrocytes in control brains (F. Original magnification, ×200).
or GFAP-expressing cells using retroviruses failed to induce gliomas unless combined with constitutive activation of Akt or deletion of Arf (38, 39). Differences between these and the present study may reflect differing methodology and/or genetic background. Nevertheless, it is clear from the present data that activation of oncogenic K-ras using GFAP-Cre is sufficient for glioma formation in a mixed FVB/C57B/6 background.

In addition to fulfilling diagnostic criteria for glioma, the tumors in GFAP-Cre+/K-rasG12D mice expressed proteins associated with NSC and GSC. The majority of tumor cells were Olig2-positive. In human glioma specimens, Olig2 is coexpressed with the majority of proliferating (Ki67-immunoreactive) cells and nearly all the CD133+ cells (25). Furthermore, Olig2 deletion abrogates the ability of Ink4a/Arf null, EGFR-vIII-transformed neurospheres to form tumors when injected into the brains of host mice (25). These observations and others have led to the suggestion that Olig2 represents a link between normal stem cells and the stem-like cells in glioma, and may be critical for human gliomagenesis (25). Many of the tumor cells (but not normal astrocytes or neurons) in our model also expressed cytoplasmic PDGFR-α. A subset of GFAP-expressing (type B cells) in the normal SVZ expresses PDGFR-α (21). Furthermore, overexpression of PDGFR-α is a common finding in both low- and high-grade gliomas, and may facilitate tumor cell migration in these highly infiltrative neoplasms (26, 29). Finally, the tumor cells in GFAP-Cre+/K-rasG12D mice express high levels of nuclear Bmi-1 protein. Bmi-1, a transcriptional repressor of the Ink4a/Arf locus, is required for the self-renewal capacity of neural and hematopoietic stem cells and is overexpressed in a variety of human cancers (27, 40, 41). The expression of NSC- and GSC-associated markers by infiltrating tumor cells in our model indicates their stem-like qualities and suggests that they may arise from K-ras–transformed endogenous NSCs.

Indeed, the SVZ/RMS in GFAP-Cre+/K-rasG12D mice was markedly expanded and included nonoverlapping GFAP-expressing and TUJ1–expressing populations of cells. Expression of the GFAP-Cre transgene and activation of the Ras pathway in these cells was confirmed with immunohistochemistry for Cre and p-MAPK. Evidence suggests that the GFAP-expressing cells of the SVZ (type B cells) constitute the true stem cell in this stem/progenitor cell niche, giving rise to transit-amplifying cells, which, in turn, produce TUJ1–positive, immature neurons (type A cells; ref. 14). Our data suggest that expression of oncogenic K-ras in GFAP-expressing, type A cells results in proliferation of this compartment, with both symmetrical and asymmetrical division, leading to expansion of both type A cells and neuronal precursors, with loss of GFAP expression in the latter cells. The reason for the spatial segregation of the cell types is unclear but may be related to a partially retained migration program on the part of the neuronal precursors. Foci of infiltrating, proliferating, atypical cells expressing stem cell markers in continuity or close proximity to the expanded SVZ/RMS suggest that some of the stem/progenitor cells acquire the capacity to infiltrate surrounding brain, perhaps facilitated by the expression of PDGFR-α.

The expansion of the SVZ/RMS in GFAP-Cre+/K-rasG12D mice was similar to that reported with intraventricular infusion of EGF or PDGF in wild-type mice. Infusion of these upstream growth factors in the Ras signaling pathway resulted in reversible expansion of the SVZ and “glioma-like” growths in the vicinity of the ventricles (20, 21). Others have shown that p53 deletion results in focal hyperplasias of the SVZ, and after exposure to the mutagen ethylnitrosourea, high-grade gliomas develop in periventricular locations (10). Zhu and colleagues (9) showed that GFAP-Cre–mediated loss of Nf1 in a germline homozygous p53 null mice resulted in high-grade gliomas; histologic examination of animals at early time points showed that, in the majority of animals with early tumors, the neoplasms were directly associated with the SVZ. Further deletion of Pten in the Nf1/p53 model accelerates the development of glioma, which is preceded by ectopic migration of stem/progenitor cells from the SVZ (8). These data, as well as the results of our study, support the hypothesis that SVZ stem/progenitor cells can serve as cells of origin for glioma.

It is unknown in humans whether the GSC in gliomas derive from stem cells, lineage-restricted precursor cells, or dedifferentiated astrocytes. It is possible that GSC arise through neoplastic transformation of cells at multiple and various stages along the spectrum of differentiation. If so, an important question is whether the differentiation status of the cell of origin determines the particular glioma phenotype in humans, and whether this has prognostic or therapeutic implications. Interestingly, a recent study showed differences in the clinical behavior of high-grade gliomas based on proximity to the SVZ, as evaluated by preoperative magnetic resonance imaging. Tumors that were in contact with the SVZ upon initial presentation were more likely to be multifocal and were more likely to recur in locations that were noncontiguous with the primary lesion (42). On the other hand, in an orthotopic transplant model, Bachoo et al. (12) reported that expression of

---

**FIGURE 5.** The tumor cells expressed markers associated with NSC and GSC. Olig2 immunohistochemistry highlighted foci of tumor (A, Original magnification, ×40; boxed region at higher magnification in B). The brown, nuclear reaction product was seen in tumor cells encircling Olig2-negative neurons (B, Original magnification, ×400). The cytoplasm of atypical, neoplastic cells was marked brown using antibody to PDGFR-α (C, Original magnification, ×400). A Nova Red chromagen stains the infiltrating tumor cell nuclei with Bmi-1 immunohistochemistry (D, Original magnification, ×400).
constitutively active EGFR in Ink4a/Arf-deficient, mature astrocytes leads to apparent dedifferentiation, including loss of GFAP expression, up-regulation of nestin, and reacquisition of neurosphere-forming ability. Furthermore, in a small number of animals, there was no difference in histopathology or survival when mice were transplanted with Ink4a/Arf-deficient, mutant EGFR-expressing NSC compared with mature astrocytes with the same genetic manipulations (12). However, Bruggeman and colleagues (43) recently showed that tumors with more aggressive histology develop in mice transplanted with Bmi-1-deficient, Ink4a/Arf-null, mutant EGFR-expressing astrocytes when compared with tumors formed from NSC with the same genetic manipulations. Further work is required to resolve these issues.

In summary, our results show that the GFAP-Cre transgene can be used to target expression of oncogenic K-ras to glioneuronal precursor cells and adult NSC in vivo. Hyperactive Ras signaling alone is sufficient to produce gliomas that closely resemble human tumors. In addition, hyperactive Ras signaling in cells of the SVZ results in a marked expansion of this stem/progenitor cell compartment. Although other possibilities cannot be entirely excluded, the expression of stemness markers by tumor cells and the proximity of tumor to the expanded SVZ/RMS support the hypothesis that the SVZ/RMS is the source of infiltrating tumor cells in this model. A better understanding of the cell of origin in glioma, and whether its differentiation status affects the histopathologic and clinical behavior, may have implications for glioma classification, treatment and prognosis.

Materials and Methods

Generation of GFAP-Cre+/KrasG12D Mice

K-rasG12D mice were a gift from Dr. Tyler Jacks. The genetic manipulation in these mice targets oncogenic K-ras(K-rasG12D) to the endogenous K-ras locus (44). The allele has a stop codon flanked by loxP sites. Cre recombinase–mediated excision of the stop cassette allows expression of the oncogenic K-ras from the endogenous K-ras promoter. GFAP-Cre mice [FVB-Tg(GFAP-cre)25Mes/J; The Jackson Laboratory] were mated with KrasG12D mice (129/SvJac/C57BL/6) to generate GFAP-Cre+/K-rasG12D and littermate control mice on a mixed 129/SvJac/C57BL/6/FVB background. GFAP-Cre mice were bred with Rosa26r mice on an FVB background for the purpose of tracing Cre-recombinase expression driven by the GFAP promoter (45). Mice were housed in the animal care facility at Vanderbilt University following the Association for Assessment and Accreditation of Laboratory Animal Care guidelines. All animal procedures were approved by the Vanderbilt Institutional Animal Care and Use Committee.

Genotyping of Transgenic Mice

Identification of the GFAP-Cre allele and KrasG12D recombined alleles were determined by PCR at age 3 wk by using oligonucleotide primers as described previously (44, 46).
β-Galactosidase Histochemistry

Brains from GFAP-Cre+/Rosa26r mice were fixed in 4% paraformaldehyde and stained for β-galactosidase expression using standard techniques. The tissues were dehydrated to 70% ethanol, embedded in paraffin, sectioned at 5 μm, and counterstained with Neutral Fast Red.

Histology and Immunohistochemistry

Mice were anesthetized with Ketamine (120 mg/kg) and Xylazine (10 mg/kg) and terminally perfused transcardially with 30 mL of 4% paraformaldehyde. Brains were removed, fixed in 4% paraformaldehyde overnight, and followed by fixation in 70% ethanol. A midsagittal cut separated the hemispheres. Additional parasagittal sections were generated from one hemisphere, and the opposite hemisphere was sectioned in the coronal plane. Tissue sections were embedded in paraffin, and sectioned at 5 μm. The sections were stained with H&E or were immunostained using antibodies for Bmi-1 (05-637; Upstate; 1:200), Cre (PRB-106C; Covance; 1:125), GFAP (sc9065; Santa Cruz Biotechnology; 1:100), Ki67 (VP-K451; Vector 1:200), Cre (PRB-106C; Covance; 1:125), GFAP (sc9065; Santa Cruz Biotechnology; 1:100), Ki67 (VP-K451; Vector Laboratories; 1:200), Olig-2 (AB9610; Chemicon; 1:500) PDGFR-α (E2691; Spring Bioscience; ready-to-use), phosphorylated Histone H3Ser10 (60-570; Upstate; 1:2000) phosphorylated p-44/42 MAPKThr202/Tyr204 (4176S; Cell Signaling; 1:100), and TUJ1 (MMS-435P; Covance; 1:100).

Measurement of the SVZ

H&E-stained, parasagittal sections from GFAP-Cre+/K-ras G12D and littermate controls were matched based on anatomical landmarks, including the size and configuration of the hippocampus. In this orientation, the SVZ/RMS has a nearly horizontal segment subjacent to the corpus callosum, and an oblique portion that connects to a nearly vertical section. The width of the SVZ at its widest point in the vertical section was measured perpendicular to the ependymal layer at ×400 using an Olympus BX41 microscope, an Olympus DP70 camera and DP controller software with calibrated digital scalebar. Means were calculated and differences between groups evaluated with Student’s t test.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. Michael Cooper for helpful comments on the manuscript and Dr. Tyler Jacks (Massachusetts Institute of Technology, Cambridge, MA) for the K-rasG12D mice, Jennifer Hofecker and Tracie Moss for expert assistance with tissue processing and sectioning, and Jean McClure for help with preparation of the manuscript.

References


Molecular Cancer Research

GFAP-Cre–Mediated Activation of Oncogenic K-ras Results in Expansion of the Subventricular Zone and Infiltrating Glioma

Ty W. Abel, Cara Clark, Brian Berie, et al.


Updated version  Access the most recent version of this article at: doi:10.1158/1541-7786.MCR-08-0477

Cited articles  This article cites 45 articles, 16 of which you can access for free at: http://mcr.aacrjournals.org/content/7/5/645.full.html#ref-list-1

Citing articles  This article has been cited by 8 HighWire-hosted articles. Access the articles at: /content/7/5/645.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.